Home > Healthcare > Pharmaceuticals > Finished Drug Form > Peptide Therapeutics Market
Peptide Therapeutics Market was evaluated to be around USD 39.3 billion in 2022 and is projected to witness massive growth at a CAGR of around 7.5% from 2023 to 2032. The rising prevalence of chronic diseases such as diabetes, obesity, and cancer has increased the demand for more effective and tailored treatments.
For instance, according to National Diabetes Statistics Report for 2022, diabetes affected 37.3 million individuals, or 11.3% of the population in the U.S. and it has been diagnosed in an estimated 28.7 million people in 2019. In addition, according to Centers for Disease Control and Prevention (CDC), over 37 million Americans have diabetes, with around 90-95% of them having type 2 diabetes. Type 2 diabetes is most common in people over the age of 45, although it is also growing more prevalent in children, teenagers, and young adults.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Peptide Therapeutics Market Size in 2022: | USD 39.3 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 7.5% |
2032 Value Projection: | USD 82.6 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 260 |
Tables, Charts & Figures: | 407 |
Segments covered: | Type, Application, Route of administration, Manufacturer Type, Synthesis Technology, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Peptides consist of short chains of amino acids connected by peptide bonds. Peptide therapeutics serve as crucial replacement therapies that supplement peptide hormones when there are insufficient endogenous levels. Peptides bind to specific surface receptors and their ligands on cells, thus aiding in the treatment of diseases by influencing the cell membrane.